<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919551</url>
  </required_header>
  <id_info>
    <org_study_id>VCP1-Ⅰ-05</org_study_id>
    <nct_id>NCT04919551</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects</brief_title>
  <official_title>A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu vcare pharmaceutical technology co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu vcare pharmaceutical technology co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will adopt a randomized, open-label, single-dose, 3-cycle, 3-way&#xD;
      crossover design to explore the PK and PD profiles of a single oral dose of vicagrel capsules&#xD;
      under fasted and fed conditions in health subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Actual">October 20, 2021</completion_date>
  <primary_completion_date type="Actual">October 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-center, randomized, open-label, single-dose, fasted/high-fat meal/low-fat meal, 3-cycle, 3-way crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 hours</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Peak concentration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>KGD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration after fasting/high-fat meal/low-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration after high-fat meal/low-fat meal/fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration after low-fat meal/fasting/high-fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vicagrel</intervention_name>
    <description>Oral administration after fasting/high-fat meal/low-fat meal</description>
    <arm_group_label>DKG</arm_group_label>
    <arm_group_label>GDK</arm_group_label>
    <arm_group_label>KGD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary signing of informed consent before the trial, and full understanding of the&#xD;
             experimental content, process and possible ARs;&#xD;
&#xD;
          -  Able to complete the study according to the protocol;&#xD;
&#xD;
          -  Subjects (and their partners) are willing to take effective contraceptive measures&#xD;
             from screening to 6 month after the last dose of the IMPs. See Appendix 5 for specific&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  Male and female subjects aged 18 to 45 years (inclusive);&#xD;
&#xD;
          -  Male weight ≥50 kg, female weight ≥ 45 kg. Body mass index (BMI) = body weight (kg) /&#xD;
             height2 (m2). BMI ranging from 18 to 28 kg/m2 (including critical values);&#xD;
&#xD;
          -  Physical examination and vital signs are normal or abnormal without clinical&#xD;
             significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 5 cigarettes per day on average 3 months before the trial;&#xD;
&#xD;
          -  Allergic constitution (allergic to multiple drugs and foods), or known to be possibly&#xD;
             allergic to drugs of the same class of the IMP or highly sensitive to clopidogrel;&#xD;
&#xD;
          -  History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25&#xD;
             mL of spirits, or 100 mL of wine); history of drug abuse or use of hard drug within&#xD;
             the past five years;&#xD;
&#xD;
          -  Blood donation or massive blood loss (&gt;450 mL) within 3 months before screening;&#xD;
&#xD;
          -  Presence of dysphagia or history of any gastrointestinal and hepatic, renal disease&#xD;
             (whether cured or not) or history of surgery that affects absorption or excretion of&#xD;
             the IMP within 6 months prior to screening;&#xD;
&#xD;
          -  With any disease that increases the risk of bleeding, such as acute gastritis, stomach&#xD;
             and duodenal ulcers, or history of abnormal bleeding (e.g. bleeding time prolonged&#xD;
             after tooth extraction);&#xD;
&#xD;
          -  The subject or his or her immediate family member has a family history of coagulation&#xD;
             or haemorrhagic disorders (such as haemophilia)/symptoms (such as hematemesis, melena,&#xD;
             severe or recurrent epistaxis, coughing blood (hemoptysis), obvious hematuria or&#xD;
             intracranial hemorrhage), or suspected vascular malformation, such as aneurysm or&#xD;
             early-onset stroke;&#xD;
&#xD;
          -  Took potent inhibitors and/or inducers of CYP enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and&#xD;
             3A5) within 28 days prior to the first dose. Potent inhibitors of CYP enzymes include&#xD;
             ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin,&#xD;
             etc.. Potent inducers of CYP enzymes include rifampicin, carbamazepine, phenytoin&#xD;
             sodium, St. John's wort, etc.. See Appendix 6 for details;&#xD;
&#xD;
          -  Took any prescription, non-prescription, any vitamin or herbal drugs within 14 days&#xD;
             before the first dose;&#xD;
&#xD;
          -  Had foods that affect CYP3A4 metabolism within 2 weeks prior to the first dose, such&#xD;
             as grapefruit or grapefruit-containing beverages, or had intense physical exercise&#xD;
             (e.g. strength training, aerobic training, and playing football) within 7 days prior&#xD;
             to the first dose, or other factors affecting drug absorption, distribution,&#xD;
             metabolism, excretion, etc.;&#xD;
&#xD;
          -  Recently there have been major changes in diet or exercise habits;&#xD;
&#xD;
          -  Participated in a another clinical study within 3 months prior to screening (a subject&#xD;
             may be enrolled if he/she withdraws from the study prior to treatment, i.e., the&#xD;
             subject is not randomized or doesn't receive treatment);&#xD;
&#xD;
          -  Failure to tolerate high-fat meals (two boiled eggs, one slice of toast with butter&#xD;
             and bacon, a box of French fries, a glass of whole milk);&#xD;
&#xD;
          -  12-lead ECG abnormalities have clinical significance;&#xD;
&#xD;
          -  Female subjects who are in lactation or positive for serum pregnancy test in the&#xD;
             screening period or during the trial;&#xD;
&#xD;
          -  Clinical laboratory abnormalities have clinical significance or other clinically&#xD;
             significant diseases before screening (including but not limited to gastrointestinal,&#xD;
             kidney, liver, nerve, blood, endocrine, tumor, and lung, immune, mental or&#xD;
             cardiovascular and cerebrovascular diseases);&#xD;
&#xD;
          -  Positive for viral hepatitis (including hepatitis B and C), HIV antibody and treponema&#xD;
             pallidum antibody during screening;&#xD;
&#xD;
          -  Any acute diseases or concomitant medicines from screening period to before taking the&#xD;
             IMPs;&#xD;
&#xD;
          -  Took chocolate, any food or drink with caffeine or xanthine within 24 hours before the&#xD;
             first dose;&#xD;
&#xD;
          -  Took any alcoholic product or alcohol breath test is positive within 24 hours before&#xD;
             the first dose;&#xD;
&#xD;
          -  Urine drug screening positive;&#xD;
&#xD;
          -  The investigator believes that there are other factors that are not suitable for&#xD;
             participating in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

